1.6Exocyclic methylene at X3
A carbonyl methylenation converts a ketone at X3 to a terminal alkene. The exocyclic double bond keeps X3 trigonal planar and presents a nonpolar methylene group to the binding surface.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A carbonyl methylenation converts a ketone at X3 to a terminal alkene. The exocyclic double bond keeps X3 trigonal planar and presents a nonpolar methylene group to the binding surface.
A photochemical [2+2] cycloaddition joins ethylene across an X2–X3 alkene. The resulting cyclobutane fixes the relative geometry of the two junction carbons.
Two carbon–carbon bonds from the same core carbon connect to opposite ends of a four-carbon chain. The five-membered ring and core share one tetrahedral carbon, which directs the cyclopentane out of the core ring plane.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A sulfone group, —S(O)₂—, replaces the thioether linker between the fused heterocyclic core and R2. The sulfone connects the same two attachment atoms through sulfur, and both compounds retain the same core substituents and R2 ring. A purified ubiquitin-specific protease assay measures concentration–response curves for the pair under identical enzyme and substrate conditions.
A thiocarbonyl group, C═S, replaces C═O at X3 in a matched pair of fused heterocycles. Both structures retain the same ring bonds at X3, the same linker, and the same peripheral substituents. The assay measures initial substrate cleavage rates across a concentration series for each compound and uses compound-only wells to measure fluorescence background.
A matched series connects the same fused heterocyclic core and R2 ring through one, two, or three consecutive methylene groups. Each series member has hydrogen at both substituent positions on every linker carbon and retains the same attachment atoms on the core and R2 ring. An eight-point concentration series with threefold dilution measures how linker length affects inhibition of the same ubiquitin-specific protease under fixed assay conditions.
A surface plasmon resonance flow cell carries an immobilized ubiquitin-specific protease on a sensor surface and a protein-free reference surface in a parallel channel. A concentration series of the fused heterocycle flows across both channels in matched buffer and solvent, followed by buffer alone to record dissociation. The reference-subtracted response at each concentration provides an equilibrium binding curve for estimating affinity.
A structure enumeration program accepts an atom-mapped fused heterocycle and a table of allowed atom and substituent changes. It generates one change per structure, checks valence and aromaticity, applies the restriction on the X1 nitrogen and X3 NH pairing, and removes duplicate structures. The program joins the resulting structures to measured protease inhibition values and reports matched pairs with their activity differences.
Phosphorus forms a single bond to each neighboring ring atom and to a methyl group. The phosphoryl oxygen provides a hydrogen-bond acceptor at the ring junction region.
Palladium-catalyzed coupling joins a halogenated aromatic core to a terminal ethynyl derivative of R2. The two sp-hybridized carbons hold the attachment vectors along the same axis.
The linker bonds to the central carbon of the tert-butyl group. The three methyl branches provide a compact nonpolar surface for contact with a hydrophobic pocket.
X5 is a pyridine-like nitrogen, and X4, X6, and X7 are carbon atoms bearing hydrogen. The X5 lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.
R5 is a nitrile attached through its carbon to a core ring carbon. The linear C≡N group places the terminal nitrogen along the axis of the attachment bond.
R1 is a 2-hydroxyethyl group attached through its first carbon. The two-carbon chain places a primary alcohol at the end of two rotatable carbon–carbon bonds.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms.A · US 8,809,532 B2 · ¶ 63
M1, M2, M3 and M4 are each independently selected from the group consisting of N and —CR6;B · US 11,136,324 B2 · ¶ 11
R5 is halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, —(CH2)nC(O)R12, —(CH2)nC(O)NR12R13, —(CH2)nC(O)OR12, —(CH2)nNR12R13, —(CH2)nNR13C(O)R12, —(CH2)nNR13S(O)mR12, —(CH2)nOR12, —(CH2)nS(O)mR12, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R6 is independently hydrogen, deuterium, halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, —(CH2)nC(O)R9, —(CH2)nC(O)NR10R11, —(CH2)nC(O)OR9, —(CH2)nNR10R11, —(CH2)nNR10C(O)R9, —(CH2)nNR10S(O)mR9, —(CB · US 11,136,324 B2 · claim 1
Y is —C(O)—; each Ra is independently halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, —(CR9R10)n—, alkenyl, alkynyl, —(CH2)nC(O)R9, —(CH2)nC(O)NR10R11, —(CH2)nC(O)OR9, —(CH2)nNR10R11, —(CH2)nR10C(O)R9, —(CH2)nNR10S(O)mR9, —(CH2)nOR9, —(CH2)nS(O)mR9, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally and independently substituted by one or more subB · US 11,136,324 B2 · claim 1
The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non adjacent atoms of the ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoA · US 8,809,532 B2 · ¶ 62
The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle.A · US 8,809,532 B2 · ¶ 63
or, any two Ra on ring B can form a new cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the newly formed cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CR9R10)n—, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(B · US 11,136,324 B2 · ¶ 42
The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 2-methyl-6-[(E)-2-(6-methylpyridin-3-yl)vinyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-[(6-methylpyridin-3-yl)ethynyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-(pyridin-3-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-(pyridin-4-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 6-[(E)-2-(6-methylpyridin-3-yl)vA · US 8,809,532 B2 · claim 6
ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(O)OR9, —(CH2)nS(O)mR9, —(CH2)nNR10R11, —(CH2)nC(O)NR10R11, —(CH2)nC(O)NHR10, —(CH2)nB · US 11,136,324 B2 · ¶ 15
In one embodiment, Q is substituted or unsubstituted monocyclic aryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted monocyclic heteroaryl, or substituted or unsubstituted bicyclic heteroaryl, wherein Q, when substituted, is independently substituted with 1, 2, 3, 4, or 5 substituents, wherein the substituent is halogen, cyano, C1-C5 haloalkyl, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, hydroxy, C1-C5 alkoxy, —O—C1-C5 haloalkyl, —S—C1-C5 alkyl, —S—C1A · US 8,809,532 B2 · ¶ 97
R3 is selected from the group consisting of C1-8 alkyl, C1-8 deuterated alkyl, C1-8 alkoxy, C1-8 haloalkoxy, C3-8 cycloalkyl and 3 to 10 membered heterocyclyl, wherein the C1-8 alkyl, C1-8 deuterated alkyl, C1-8 alkoxy, C1-8 haloalkoxy, C3-8 cycloalkyl and 3 to 10 membered heterocyclyl are each optionally further substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, C1-8 alkyl, C1-8 deuterated alkyl, C1-8 haloalkyl, halogen, amino,B · US 11,136,324 B2 · ¶ 77
An empty cell means only that no passage was reproduced there.
Treatment of dementias of various types, such as but not limited to, Alzheimer's disease (AD), Parkinson's disease, Huntington's disease and other forms, continue to be unmet medical needs.A · US 8,809,532 B2 · ¶ 4
The present invention relates to indole and indoline derivatives, compositions comprising these indole and indoline derivatives, and methods of preventing or treating disease conditions such as neurodegeneration or neuropsychiatric disorders using such compounds and compositions.A · US 8,809,532 B2 · ¶ 3
At present, there are no drugs approved for treating NASH.B · US 11,136,324 B2 · ¶ 5
ASK1 inhibitors have great potential for the clinical treatment of NASH, and have potential valuable application in the treatment of other diseases including neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune metabolic diseases and the like.B · US 11,136,324 B2 · ¶ 5
patent.fyi, US 2026/0356832 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356832/, SHA-256 a54dd869db4573424843119a6951f663c36a8bb6e3dd73a361348eaa90f04f18